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side effects, which may be prevented with prophylactic
prescription of misoprostol, omeprazole, or famotidine.
Recently marketed COX-2 specific inhibitor (COX-2) af-
fords protection against gastropathy. OBJECTIVE: To
assess cost-effectiveness of NSAIDs vs COX-2 and NSAIDs
with co-treatments to prevent GI toxicity in the treatment
of RA. METHODS: Markov models were used to simu-
late a cohort of RA patients with approximately 2.5:1 fe-
male to male ratio and 50 years, taking disease modifying
antirheumatic drugs and one of following strategies:
NSAIDs without prophylaxis, COX-2, NSAIDs with mis-
oprostol, omeprazole, or famotidine. Data on incidence,
costs and consequences of adverse events from treat-
ments were taken from the literature. Costs were mea-
sured in 1999 US dollars and health effects expressed as
quality-adjusted life years (QALYs). Sensitivity analyses
were performed. Costs and health outcomes were dis-
counted at a rate of 3% per year. RESULTS: Among the
strategies to prevent GI toxicity, COX-2 was the most
cost-effective strategy and famotidine was the least cost-
effective strategy. The incremental C/E (cost/effective-
ness) ratio between no prophylaxis and COX-2 is 62,278
($/QALY). Sensitivity analyses using incidence rates were
robust. CONCLUSIONS: COX-2 is the best option
among the strategies to prevent GI toxicity. However, the
incremental C/E between no prophylaxis and COX-2
strategies is over 60,000 ($/QALY).
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OBJECTIVE: To compare the total costs associated with
two different anti-TNF agents used in the treatment of
moderate to severe rheumatoid arthritis: etanercept, which
can be administered at home by a subcutaneous injection,
versus infliximab, which requires an intravenous infusion in
day-care. METHODS: An economic model was con-
structed to determine the costs of both treatments. The cost
Strategy QALY Costs ($)
C/E
($/QALY)
No prophylaxis 11.45 43,474 —
Misoprostol 11.53 52,817 Extended Dominated
COX-2 11.68 57,798 62,278
Famotidine 11.69 87,606 Dominated
Omeprazole 11.71 63,911 203,766
evaluation included direct medical, direct non-medical and
indirect costs. The perspective was that of the Dutch soci-
ety. The analysis was performed for the adult RA popula-
tion eligible for treatment with both agents. The base case
analysis compared a monotherapy with etanercept versus a
combination therapy with infliximab-MTX. Data for the
economic model came from published literature, expert
opinion and official price and tariff lists. RESULTS: The
analysis from the society perspective showed that the total
annual drug costs per patient do not differ substantially be-
tween infliximab and etanercept, with costs of NLG 31,526
(EURO 14,306) and NLG 31,334 (EURO 14,219) respec-
tively. However the other medical costs are substantially
higher for infliximab, which is due to the additional costs
associated with day-care and use of MTX (NLG 12,621;
EURO 5,727). Overall treatment with infliximab is more
expensive than treatment with etanercept with total costs of
NLG 45,115 (EURO 20,472) and NLG 31,621 (EURO
14,349), respectively (43.7% increase). The sensitivity anal-
ysis showed that the results vary with dosing and dosing in-
terval for infliximab. CONCLUSION: Based on the as-
sumptions used in the model, we may conclude that the use
of etanercept compares favourable with infliximab: the to-
tal costs are substantially lower, while the clinical outcomes
of etanercept are at least equivalent to those of infliximab.
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OBJECTIVE: To evaluate the total resource consump-
tion and the costs for diagnostics and treatments per pa-
tient with severe chronic polyarthritis (cp) from the third
party payers’ (TPP) perspective in Germany. METH-
ODS: A retrospective cross-sectional cost of illness-study
was performed. Patients (18 to 75 years) with acute dis-
ease activity of cp with a history of therapy failure with
MTX over a minimum of 4 months or failure of more
than one basic treatment were included. Hospital and
practice data was abstracted from patient’s records. Sta-
tistical analysis and cost evaluation were performed by
using the SAS package. Cost data was taken from pub-
lished German tariff and price lists. RESULTS: The mean
age of the patients was 56 years, 71.2% were females.
The mean onset of the disease was 11.2 years ago. The
total average costs of outpatient care (n  191 patients)
were approximately 3,445 DM (95% CI: 2,981-3,907
DM) and for inpatient care (n  76 patients) 10,433 DM
(95% CI: 8,800–12,067 DM) per year. Concerning out-
patient care drug therapy could be identified as the most
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relevant cost driver (69% of the total costs) followed by
diagnostic procedures (10%). The duration of the stay in
hospital is the decisive factor for the costs of inpatient
care from TPP’s perspective in Germany. The average
hospitalization length was 19.5 days. Assuming a hospi-
talization rate of 10% the direct medical costs per cp pa-
tient and year were 4,488 DM. CONCLUSION: It could
be shown that treatment of chronic polyarthritis is as
cost-intensive as other chronic diseases. Because of the
growing interest in the development of new concepts of
patient care (e.g. disease management), further cost and
outcome data should be assessed to show the relative
value for money (e.g. with cost-effectiveness analysis) in
order to guarantee an appropriate allocation of resources.
PAO4
COX-II INHIBITORS AND NSAIDS: FINDINGS OF 
A NICE SUBMISSION
Dickson AJ
Consultant Health Economist, c/o Primary Care Rheumatology 
Society, Northallerton, N. Yorkshire, UK
The National Institute of Clinical Excellence (NICE) is
conducting an appraisal of the new COX-II specific in-
hibitors (celecoxib and rofecoxib). NICE asked the Pri-
mary Care Rheumatology (PCR) society to comment on
the ‘real-life’ clinical and cost-effectiveness of the COX-II
specific inhibitors against NSAIDs and the COX-II selec-
tive inhibitors (etodolac and meloxicam) in the treatment
of arthritis. This poster summarises the findings of the
PCR’s NICE submission. OBJECTIVES: To use evi-
dence-based medicine to compare the ‘real-life’ clinical
and cost-effectiveness of the COX-II specifics versus
NSAIDs and the COX-II selectives, in the treatment of
arthritis and prevention of drug-related gastro-intestinal
(GI) adverse events in primary-care. METHODS: Using
PubMed, a literature review of NSAIDs, COX-II inhibi-
tors (celecoxib, etodolac, meloxicam and rofecoxib) and
‘best-practice’ guidelines in the treatment of arthritis was
undertaken. The review concentrated on the problems of
NSAID-related GI adverse events, their associated treat-
ment costs and whether COX-II inhibitors provide alter-
native, clinically and cost-effective methods of treating
arthritis. RESULTS: NSAID-related GI risk rises signifi-
cantly with patient age. In the UK, NSAID-related deaths
average 2,600 patients annually. The mean, NHS cost of
NSAID-related, GI adverse events is an extra £48 per
NSAID patient per year. COX-II specifics have signifi-
cantly better GI tolerability to NSAIDs. But COX-II spe-
cifics cost the NHS an extra £40.15 minimum annually
for the average NSAID patient. COX-II selectives are
cheaper than COX-II specifics and have significantly higher
GI tolerability than NSAIDs. CONCLUSIONS: COX-II
inhibitors represent a more clinically effective solution
for treating arthritis and reducing GI adverse events in
primary care than NSAIDs. There is a lack of ‘real-life ev-
idence’ to determine for which at risk patients COX-II
specifics are cost-effective over the COX-II selectives and
NSAIDs. Best-practice guidelines support the view that
there is a role for COX-II specifics, COX-II selectives and
NSAIDs in treating arthritis in primary care.
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OBJECTIVE: To summarise the state of knowledge in
terms of economic impact of rheumatoid arthritis (RA), to
highlight the level of aggregation of categories of costs in
different economic evaluations and to identify the burden
of productivity costs in RA. METHODS: Several comput-
erised databases (Medline, Embase, Econlit, OHE HEED,
NHS EED) were searched to identify the relevant studies
for the review. Among the hundreds of records found, 18
were selected for the analysis. The majority of them were
cost of illness studies. At the first stage three main catego-
ries of costs were considered (medical direct costs, non-
medical direct costs, productivity costs) and the economic
impact of each category was quantified. Then subcatego-
ries of costs were investigated in order to assess the grade
of homogeneity in the level of aggregation among differ-
ent studies. RESULTS: Direct medical costs were included
in every study. Total average direct medical costs were in
the range of US$6000 per year (per patient). Among
them, hospital costs constituted in general the largest
amount (from 25 to 40%) followed by medications and
arthritis professional visits. There was considerable lack
of homogeneity in the assessment of cost categories.
Many studies showed a skewed distribution of costs
among patients in relation to their level of severity. Non-
medical direct costs were in general not substantial. By
contrast the economic impact of indirect costs has re-
sulted extremely high, ranging from 1 to 3–4 times the di-
rect costs. Productivity costs are likely to be underesti-
mated given the difficulty of assessing the costs associated
with premature mortality. CONCLUSION: The literature
review indicated a strong need for a standardization in the
assessment of relevant costs for RA. Although there were
differences in the level of aggregation, all studies reported
productivity costs to be the largest category. New drugs
with the ability to reduce the long-term consequences of
RA are likely to have a significant economic impact.
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